Milestone Pharmaceuticals shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $9 price target.
Portfolio Pulse from Benzinga Newsdesk
Milestone Pharmaceuticals shares rose after Rodman & Renshaw initiated coverage with a Buy rating and a $9 price target.
August 22, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rodman & Renshaw initiated coverage on Milestone Pharmaceuticals with a Buy rating and a $9 price target, leading to a rise in the stock price.
The initiation of coverage with a Buy rating and a specific price target by a financial firm often leads to increased investor interest and buying activity, which can drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100